RATIONALE: [18F]Fallypride is a new and promising radiotracer, suitable for imaging D2 receptors with Positron Emission Tomography (PET) in both striatal and extrastriatal regions. The high signal to noise ratio of [18F]fallypride has been attributed to its high affinity for D2 receptors (K(D) of 0.03 nM, measured in vitro at room temperature). OBJECTIVES: We sought to further characterize this tracer in terms of its in vivo affinity, possible affinity differences between brain regions and dependence of in vitro affinity on temperature. METHODS: PET scans were performed in baboons over a wide range of concentrations to measure the in vivo K(D) of [18F]fallypride in striatal and extrastriatal regions. Several analytical approaches were used, including nonlinear kinetic modeling and equilibrium methods. Also, in vitro assays were performed at 22 and 37 degrees C. RESULTS: No significant differences in the in vivo K(D) were detected between regions. In vivo K(D) of [18F]fallypride was 0.22+/-0.05 nM in striatum, 0.17+/-0.05 nM in thalamus, and 0.21+/-0.07 nM in hippocampus. These values were intermediate between in vitro K(D) measured at 22 (0.04+/-0.03 nM) and 37 degrees (2.03+/-1.07 nM). CONCLUSION: The in vivo affinity of [18F]fallypride was not as high as previously estimated from in vitro values. This property might contribute to the favorable kinetic properties of the tracer. The in vivo affinity was similar between striatal and extrastriatal regions. This result indicates that the measured regional in vivo affinities of this tracer are not affected by putative regional differences in endogenous dopamine, and that [18F]fallypride is an appropriate tool to provide unbiased estimates of the occupancy of D2 receptors by antipsychotic drugs in striatal and extrastriatal regions.
RATIONALE: [18F]Fallypride is a new and promising radiotracer, suitable for imaging D2 receptors with Positron Emission Tomography (PET) in both striatal and extrastriatal regions. The high signal to noise ratio of [18F]fallypride has been attributed to its high affinity for D2 receptors (K(D) of 0.03 nM, measured in vitro at room temperature). OBJECTIVES: We sought to further characterize this tracer in terms of its in vivo affinity, possible affinity differences between brain regions and dependence of in vitro affinity on temperature. METHODS: PET scans were performed in baboons over a wide range of concentrations to measure the in vivo K(D) of [18F]fallypride in striatal and extrastriatal regions. Several analytical approaches were used, including nonlinear kinetic modeling and equilibrium methods. Also, in vitro assays were performed at 22 and 37 degrees C. RESULTS: No significant differences in the in vivo K(D) were detected between regions. In vivo K(D) of [18F]fallypride was 0.22+/-0.05 nM in striatum, 0.17+/-0.05 nM in thalamus, and 0.21+/-0.07 nM in hippocampus. These values were intermediate between in vitro K(D) measured at 22 (0.04+/-0.03 nM) and 37 degrees (2.03+/-1.07 nM). CONCLUSION: The in vivo affinity of [18F]fallypride was not as high as previously estimated from in vitro values. This property might contribute to the favorable kinetic properties of the tracer. The in vivo affinity was similar between striatal and extrastriatal regions. This result indicates that the measured regional in vivo affinities of this tracer are not affected by putative regional differences in endogenous dopamine, and that [18F]fallypride is an appropriate tool to provide unbiased estimates of the occupancy of D2 receptors by antipsychotic drugs in striatal and extrastriatal regions.
Authors: J Delforge; M Bottlaender; C Loc'h; I Guenther; C Fuseau; B Bendriem; A Syrota; B Mazière Journal: J Cereb Blood Flow Metab Date: 1999-05 Impact factor: 6.200
Authors: X Xiberas; J L Martinot; L Mallet; E Artiges; M Canal; C Loc'h; B Mazière; M L Paillère-Martinot Journal: J Clin Psychopharmacol Date: 2001-04 Impact factor: 3.153
Authors: Jogeshwar Mukherjee; Bradley T Christian; Kelly A Dunigan; Bingzhi Shi; Tanjore K Narayanan; Martin Satter; Joseph Mantil Journal: Synapse Date: 2002-12-01 Impact factor: 2.562
Authors: C M Stephenson; V Bigliani; H M Jones; R S Mulligan; P D Acton; D Visvikis; P J Ell; R W Kerwin; L S Pilowsky Journal: Br J Psychiatry Date: 2000-11 Impact factor: 9.319
Authors: Chelsea L Robertson; Kenji Ishibashi; Mark A Mandelkern; Amira K Brown; Dara G Ghahremani; Fred Sabb; Robert Bilder; Tyrone Cannon; Jacqueline Borg; Edythe D London Journal: J Neurosci Date: 2015-04-15 Impact factor: 6.167
Authors: Kendra L Seaman; Christopher T Smith; Eric J Juarez; Linh C Dang; Jaime J Castrellon; Leah L Burgess; M Danica San Juan; Paul M Kundzicz; Ronald L Cowan; David H Zald; Gregory R Samanez-Larkin Journal: Hum Brain Mapp Date: 2019-04-01 Impact factor: 5.038
Authors: Sarah A Eisenstein; Jon M Koller; Marilyn Piccirillo; Ana Kim; Jo Ann V Antenor-Dorsey; Tom O Videen; Abraham Z Snyder; Morvarid Karimi; Stephen M Moerlein; Kevin J Black; Joel S Perlmutter; Tamara Hershey Journal: Synapse Date: 2012-05-15 Impact factor: 2.562
Authors: Michele S Milella; Aryandokht Fotros; Paul Gravel; Kevin F Casey; Kevin Larcher; Jeroen A J Verhaeghe; Sylvia M L Cox; Andrew J Reader; Alain Dagher; Chawki Benkelfat; Marco Leyton Journal: J Psychiatry Neurosci Date: 2016-08 Impact factor: 6.186
Authors: M Sebold; G Spitta; T Gleich; T Dembler-Stamm; O Butler; K Zacharias; S Aydin; M Garbusow; M Rapp; F Schubert; R Buchert; J Gallinat; A Heinz Journal: J Neural Transm (Vienna) Date: 2019-02-12 Impact factor: 3.575
Authors: Kenji Ishibashi; Chelsea L Robertson; Mark A Mandelkern; Andrew T Morgan; Edythe D London Journal: Mol Imaging Date: 2013 Nov-Dec Impact factor: 4.488